237 related articles for article (PubMed ID: 35378710)
41. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
42. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.
Kent OA; Sandí MJ; Burston HE; Brown KR; Rottapel R
Oncotarget; 2017 Jan; 8(3):4484-4500. PubMed ID: 27835861
[TBL] [Abstract][Full Text] [Related]
43. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
44. Modulation of RAB5A early endosome trafficking in response to KRas mediated macropinocytic fluxes in pancreatic cancer cells.
Teske C; Schweitzer C; Palamidessi A; Aust DE; Scita G; Weitz J; Welsch T
Biochem Biophys Res Commun; 2017 Nov; 493(1):528-533. PubMed ID: 28867190
[TBL] [Abstract][Full Text] [Related]
45. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.
Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G
Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448
[TBL] [Abstract][Full Text] [Related]
46. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
[TBL] [Abstract][Full Text] [Related]
47. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
48. KRas, ROS and the initiation of pancreatic cancer.
Storz P
Small GTPases; 2017 Jan; 8(1):38-42. PubMed ID: 27215184
[TBL] [Abstract][Full Text] [Related]
49. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
50. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
51. The pervasiveness of macropinocytosis in oncological malignancies.
Commisso C
Philos Trans R Soc Lond B Biol Sci; 2019 Feb; 374(1765):20180153. PubMed ID: 30967003
[TBL] [Abstract][Full Text] [Related]
52. The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent efficacy against pancreatic cancer.
Du YB; Wang XF; Liu XJ; Li Y; Miao QF; Jiang M; Sheng WJ; Zhen YS
Biochem Pharmacol; 2022 Jul; 201():115057. PubMed ID: 35489393
[TBL] [Abstract][Full Text] [Related]
53. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
[TBL] [Abstract][Full Text] [Related]
54. Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling.
De La O JP; Murtaugh LC
Cell Cycle; 2009 Jun; 8(12):1860-4. PubMed ID: 19440048
[TBL] [Abstract][Full Text] [Related]
55. Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions.
Liou GY; Döppler H; DelGiorno KE; Zhang L; Leitges M; Crawford HC; Murphy MP; Storz P
Cell Rep; 2016 Mar; 14(10):2325-36. PubMed ID: 26947075
[TBL] [Abstract][Full Text] [Related]
56. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
57. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.
Fujimura K; Wang H; Watson F; Klemke RL
Cancer Res; 2018 Mar; 78(6):1444-1456. PubMed ID: 29321164
[TBL] [Abstract][Full Text] [Related]
58. Binge Drinking: Macropinocytosis Promotes Tumorigenic Growth of RAS-Mutant Cancers.
Hobbs GA; Der CJ
Trends Biochem Sci; 2020 Jun; 45(6):459-461. PubMed ID: 32413322
[TBL] [Abstract][Full Text] [Related]
59. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue.
Ako S; Nouso K; Kinugasa H; Dohi C; Matushita H; Mizukawa S; Muro S; Akimoto Y; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Tsutsumi K; Kato H; Okada H
Pancreatology; 2017; 17(2):285-290. PubMed ID: 28139399
[TBL] [Abstract][Full Text] [Related]
60. Eicosapentaenoic Acid Inhibits
Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
